Ontology highlight
ABSTRACT: Background
Targeting immune checkpoints that inhibit antitumor immune responses has emerged as a powerful new approach to treat cancer. We recently showed that blocking the tumor necrosis factor receptor-type 2 (TNFR2) pathway induces the complete loss of the protective function of regulatory T cells (Tregs) in a model of graft-versus-host disease (GVHD) prevention that relies on Treg-based cell therapy. Here, we tested the possibility of amplifying the antitumor response by targeting TNFR2 in a model of tumor relapse following hematopoietic stem-cell transplantation, a clinical situation for which the need for efficient therapeutic options is still unmet.Method
We developed appropriate experimental conditions that mimic patients that relapsed from their initial hematologic
SUBMITTER: Moatti A
PROVIDER: S-EPMC8987798 | biostudies-literature | 2022 Apr
REPOSITORIES: biostudies-literature